Evidence map›Paper›PMID 39599860›Full record

ReviewViruses2024

Emerging Insights into Memory Natural Killer Cells and Clinical Applications.

Jonida Kokiçi, Anucha Preechanukul, Helena Arellano-Ballestero, Frances Gorou, Dimitra Peppa

Abstract readReview
In one paragraph

Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Natural Killer Cells: Dual Regulators and Therapeutic Targets in Multiple Sclerosis Immunopathogenesis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonida KokiçiDivision of Infection and Immunity, University College London, London NW3 2PP, UK.ORCID 0009-0000-3773-492X
Anucha PreechanukulDivision of Infection and Immunity, University College London, London NW3 2PP, UK.ORCID 0000-0001-7428-0058
Helena Arellano-BallesteroCancer Institute, University College London, London WC1E 6DD, UK.
Frances GorouDivision of Infection and Immunity, University College London, London NW3 2PP, UK.ORCID 0009-0000-2890-8713
Dimitra PeppaDivision of Infection and Immunity, University College London, London NW3 2PP, UK.

Funding

Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradicationR01AI155182 · NIAID · UNIVERSITY OF OXFORD · PI PEPPA, DIMITRA · 2020 to 2024
$1.9M
NIAID NIH HHS R01 AI155182NIH HHS 566495
6 · The paper itself

Abstract

Natural killer (NK) cells are innate lymphocytes that can rapidly mount a response to their targets by employing diverse mechanisms. Due to their functional attributes, NK cells have been implicated in anti-viral and anti-tumour immune responses. Although traditionally known to mount non-specific, rapid immune responses, in recent years, the notion of memory NK cells with adaptive features has gained more recognition. Memory NK cells emerge in response to different stimuli, such as viral antigens and specific cytokine combinations. They form distinct populations, accompanied by transcriptional, epigenetic and metabolic reprogramming, resulting in unique phenotypic and functional attributes. Several clinical trials are testing the efficacy of memory NK cells due to their enhanced functionality, bioenergetic profile and persistence in vivo. The therapeutic potential of NK cells is being harnessed in viral infections, with wider applications in the cancer field. In this review, we summarise the current state of research on the generation of memory NK cells, along with their clinical applications in viral infection and cancer.

Indexed as

Immunologic MemoryKiller Cells, NaturalNeoplasmsVirus DiseasesAnimalsHumansImmunity, Innateadaptive NK cellscytokine-induced memory-like (CIML)HCMVimmunotherapymemorynatural killer (NK) cells

Identifiers

PMID39599860
PMCPMC11599065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.